Merestinib - Eli Lilly

Drug Profile

Merestinib - Eli Lilly

Alternative Names: LY-2801653

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Dana-Farber Cancer Institute; Eli Lilly; University of Utah
  • Class Amides; Antineoplastics; Dihydropyridines; Pyrazoles; Small molecules
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors; Proto oncogene protein c met inhibitors; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Bone metastases; Cancer

Most Recent Events

  • 11 Jan 2018 Phase-I clinical trials in Bone metastases in USA (PO) (NCT03292536)
  • 27 Sep 2017 Eli Lilly and University of Utah plans a phase I trial for Bone metastases (in patients with Breast cancer) (PO) (NCT03292536)
  • 12 Sep 2017 Eli Lilly completes a phase I trial in Cancer (Late-stage disease) in USA (NCT01285037)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top